StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/309% below fair value
$2.72−0.18 (-6.37%)

Close on Nov 17, 2026Market cap $1.46BP/E –Yield –

Recursion Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Recursion Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$544.01M. For fiscal 2025 it was -$648.13M. The highest annual figure on record is -$62.44M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$648.13M–
FY2024Dec 31, 2024-$479.00M–
FY2023Dec 31, 2023-$350.06M–
FY2022Dec 31, 2022-$245.73M–
FY2021Dec 31, 2021-$182.78M–
FY2020Dec 31, 2020-$84.62M–
FY2019Dec 31, 2019-$62.44M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$134.97M–
Q1 FY2026Mar 31, 2026-$128.51M–
Q4 FY2025Dec 31, 2025-$108.33M–
Q3 FY2025Sep 30, 2025-$172.20M–
Q2 FY2025Jun 30, 2025-$176.23M–
Q1 FY2025Mar 31, 2025-$191.37M–
Q4 FY2024Dec 31, 2024-$183.77M–
Q3 FY2024Sep 30, 2024-$98.35M–
Q2 FY2024Jun 30, 2024-$100.54M–
Q1 FY2024Mar 31, 2024-$96.34M–
Q4 FY2023Dec 31, 2023-$98.93M–
Q3 FY2023Sep 30, 2023-$99.55M–
Q2 FY2023Jun 30, 2023-$81.72M–
Q1 FY2023Mar 31, 2023-$69.87M–
Q4 FY2022Dec 31, 2022-$60.98M–
Q3 FY2022Sep 30, 2022-$62.57M–
Q2 FY2022Jun 30, 2022-$66.19M–
Q1 FY2022Mar 31, 2022-$55.98M–
Q4 FY2021Dec 31, 2021-$64.96M–
Q3 FY2021Sep 30, 2021-$46.40M–
Q2 FY2021Jun 30, 2021-$40.93M–
Q1 FY2021Mar 31, 2021-$30.48M–
Q4 FY2020Dec 31, 2020-$25.58M–
Q3 FY2020Sep 30, 2020-$22.47M–
Q2 FY2020Jun 30, 2020-$18.22M–
Q1 FY2020Mar 31, 2020-$18.34M–

More Recursion Pharmaceuticals figures

See a number that looks wrong?